MorphoSys offers $1.7bn for Constellation, but investors see starsShares in German biotech MorphoSys have gone on the slide after it announced a $1.7 billion deal to Share XMorphoSys offers $1.7bn for Constellation, but investors see starshttps://pharmaphorum.com/news/morphosys-offers-1-7bn-for-constellation-but-investors-see-stars/
Incyte/Morphosys take on CAR-Ts with $198,000 per year antibodyIncyte and Morphosys’ Monjuvi antibody therapy has been approved for certain patients with lymphoma, as the companies hope Share XIncyte/Morphosys take on CAR-Ts with $198,000 per year antibodyhttps://pharmaphorum.com/news/incyte-morphosys-take-on-car-ts-as-lymphoma-antibody-monjuvi-approved-in-us/
MorphoSys gets $750m from Incyte for anti-CD19 cancer drugIncyte has agreed a deal with Germany’s MorphoSys to license an antibody that could be an alternative to Share XMorphoSys gets $750m from Incyte for anti-CD19 cancer drughttps://pharmaphorum.com/news/morphosys-gets-750m-from-incyte-for-anti-cd19-cancer-drug/
Novartis’ $100m bet on eczema drug fails as MOR106 development endsGalapagos and MorphoSys have announced that they are ending the clinical development programme for their drug MOR106 in Share XNovartis’ $100m bet on eczema drug fails as MOR106 development endshttps://pharmaphorum.com/news/novartis-100m-bet-on-eczema-drug-fails-as-mor106-development-ends/
Morphosys to take on CAR-Ts in NHL with promising antibodyGermany’s Morphosys has announced results from its combination therapy of an experimental antibody and Celgene’s Revlimid in a Share XMorphosys to take on CAR-Ts in NHL with promising antibodyhttps://pharmaphorum.com/news/morphosys-to-take-on-car-ts-in-nhl-with-promising-antibody/
Novartis pays up to $1 billion for potential eczema drugSwiss pharma Novartis is to pay up to $1 billion to Galapagos and MorphoSys for exclusive rights to Share XNovartis pays up to $1 billion for potential eczema drughttps://pharmaphorum.com/news/novartis-increases-its-immunology-footprint-with-1-billion-deal/
